Share This Author
Human papillomavirus and survival of patients with oropharyngeal cancer.
Tumor HPV status is a strong and independent prognostic factor for survival among patients with oropharyngeal cancer and the risk of death significantly increased with each additional pack-year of tobacco smoking.
Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck.
Treatment of locoregionally advanced head and neck cancer with concomitant high-dose radiotherapy plus cetuximab improves locoreGional control and reduces mortality without increasing the common toxic effects associated with radiotherapy to the head andneck.
Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival.
A radiation therapy oncology group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and…
Quantification of volumetric and geometric changes occurring during fractionated radiotherapy for head-and-neck cancer using an integrated CT/linear accelerator system.
Validation of an accelerated ‘demons’ algorithm for deformable image registration in radiation therapy
The results suggest that the accelerated demons algorithm has significant potential for delineating and tracking doses in targets and critical structures during CT-guided radiotherapy.
The influence of positive margins and nerve invasion in adenoid cystic carcinoma of the head and neck treated with surgery and radiation.
Radiation response of the central nervous system.
Randomized phase III trial of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III to IV head and neck carcinoma: RTOG 0522.
- K. Ang, Q. Zhang, R. Axelrod
- MedicineJournal of clinical oncology : official journal…
- 20 September 2014
Adding cetuximab to radiation-cisplatin did not improve outcome and hence should not be prescribed routinely, and the PFS and OS were higher in patients with p16-positive OPC, but outcomes did not differ by EGFR expression.